-Adrenergic receptor (␣1-AR) is a crucial mediator of cardiac hypertrophy. Although numerous intracellular pathways have been implicated in ␣ 1-AR-induced hypertrophy, its precise mechanism remains elusive. We aimed to determine whether ␣ 1-AR induces cardiac hypertrophy through a novel signaling pathway-␣ 1-AR/epidermal growth factor receptor (EGFR)/ signal transducer and activator of transcription 3 (STAT3). The activation of STAT3 by ␣ 1-AR was first demonstrated by tyrosine phosphorylation, nuclear translocation, DNA binding, and transcriptional activity in neonatal Sprague-Dawley rat cardiomyocytes. Activated STAT3 showed an essential role in ␣ 1-AR-induced cardiomyocyte hypertrophic growth, as assessed by treatment with STAT3 inhibitory peptide and lentivirus-STAT3 small interfering RNA. The results were further confirmed by in vivo experiments involving intraperitoneal injection of the STAT3 inhibitor WP1066 significantly inhibiting phenylephrine-infusion-induced heart hypertrophy in male C57BL/6 mice. Furthermore, the ␣ 1-AR-activated STAT3 was associated with transactivation of EGFR because inhibition of EGFR with the selective inhibitor AG1478 prevented ␣ 1-AR-induced STAT3 tyrosine phosphorylation and its transcriptional activity, as well as cardiac hypertrophy. In summary, these results suggest that ␣ 1-AR induces the activation of STAT3, mainly through transactivation of EGFR, which plays an important role in ␣ 1-AR-induced cardiac hypertrophy.
␣ 1-adrenergic receptor; signal transducers and activators of transcription 3; epidermal growth factor receptor; transactivation CARDIAC HYPERTROPHY IS INITIALLY an adaptive process to counterbalance the increasing workload resulting from diverse cardiovascular diseases, whereas sustained hypertrophy can eventually lead to heart failure, a major cause of cardiac morbidity and mortality. Therefore, identifying the critical molecular mechanisms involved in hypertrophy is important for clinical treatment. The activation of adrenergic receptor (AR) induced by enhanced endogenous level of catecholamine is believed to be a primary mediator of cardiac hypertrophy (1) . ␣ 1 -AR is a G-protein-coupled receptor (GPCR) in the heart and thought to have a role in cardiac hypertrophy mainly through activated Gq proteins and their downstream signaling, such as the mitogenactivated protein kinase (MAPK) pathway (7, 45) . In addition, recent evidence suggests that G-protein-independent signal transduction pathways also contribute to the hypertrophic growth responses induced by ␣ 1 -AR (22, 33) . This suggested mechanism of ␣ 1 -AR-induced hypertrophy is complicated, and many detailed mechanisms are still unclear.
Signal transducers and activators of transcription 3 (STAT3) is one of the critical transcriptional factors that regulate cell differentiation, proliferation, and apoptosis (13) . Recently, STAT3 was found to have an important role in the development of cardiac hypertrophy (8) . Cardiac-specific overexpression of STAT3 in transgenic mice led to myocardial hypertrophy (19) , and cardiac STAT3-deficient animals showed increased susceptibility to doxorubicin-induced heart failure with advancing age (15) . STAT3 is activated by many cytokines and growth factors (17, 34, 37) to mediate hypertrophy. Moreover, STAT3 promotes cardiac hypertrophy under various stress conditions such as pressure overload (41) , myocardial infarction (14) , and anemia (27) . However, the effect of STAT3 in sympathetic activation-induced cardiac hypertrophy is unclear.
Our previous studies (44) showed that ␤-AR stimulation led to activation of STAT3 and the reexpression of atrial natriuretic factor in neonatal rat cardiomyocytes. In this study, we investigated ␣ 1 -AR also activating STAT3 in neonatal rat cardiomyocytes for an essential role in ␣ 1 -AR-induced cardiac hypertrophy. Further studies showed that the activation of STAT3 occurs mainly through transactivation of epidermal growth factor receptor (EGFR).
MATERIALS AND METHODS
Animals. Experiments were conducted in isolated rat cardiomyocytes from 1-day-old neonatal Sprague-Dawley rats and in adult male C57BL/6 mice. Animals used in this study were housed in standard cages with food and water available ad libitum. The animal room was maintained on a 12:12-h light-dark cycle. The experiments were approved by the Institutional Animal Care and Use Committee of Peking University Health Science Center (LA2010 -039) and adhered to the American Physiological Society's Guiding Principles in the Care and Use of Vertebrate Animals in Research and Training. All protocols were conducted in accordance with the Guidelines for Animal Experiments, Peking University Health Science Center.
Primary culture of neonatal rat cardiomyocytes. Cardiomyocytes were isolated and cultured from 1-day-old neonatal Sprague-Dawley rats as described previously (23) . In brief, a central thoracotomy was performed after the neonatal rats (obtained from the Medical Experimental Animal Center of Peking University Health Science Center) were deeply anaesthetized with 1.0% isoflurane (Baxter Healthcare). The hearts was quickly excised and immediately embedded in freezing Hanks' solution. Cardiomyocytes were dispersed by digestion with 0.25% trypsin (GIBCO) at 37°C. Then, isolated cardiomyocytes were cultured in DMEM (GIBCO) with 10% FBS (Hyclone) and antibiotics (50 mg/ml streptomycin and 50 U/ml penicillin) at 37°C in a 5% CO 2 atmosphere. 5-Bromodeoxyuridine (100 mol/l) was added to the culture medium to prevent proliferation of nonmyocardiocytes. Cells were serum starved for 24 h in serum-free medium before treatment. In experiments, cells were pretreated with 10 mol/l propranolol for 30 min to block ␤-AR and then stimulated with 10 mol/l norepinephrine (NE) to active ␣ 1-AR.
Western blot analysis. Cell lysates and heart extracts were separated on 8%Ϫ10% SDS-PAGE and then transferred by electroblotting to nitrocellulose membranes. The membranes were incubated with the antibodies against STAT3, STAT1, eIF5, GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA), phospho-STAT3, phospho-EGFR, or EGFR (Cell Signaling, Danvers, MA). Protein bands were visualized by the use of a super-Western sensitivity chemiluminescence detection system (Pierce). Autoradiographs were quantitated by densitometry (Science Imaging System, Bio-Rad).
[ 3 H]leucine incorporation. Cardiomyocytes were pretreated with or without inhibitory agents and then incubated for 48 h with NE after pretreatment with propranolol. [ 3 H]leucine (1 Ci/ml; Amersham Biosciences, UK) was added 6 h before harvesting. After incubation, cells were kept for 30 min with 10% trichloroacetic acid at 4°C to precipitate proteins. The precipitates were then solubilized in 0.1 mol/l NaOH at 37°C for 1 h. The incorporated radioactivity was determined by liquid scintillation spectrometry (Beckman Coulter, Fullerton, CA).
Construction of lentiviral vector for silencing rat STAT3 expression. Small interfering RNAs (siRNAs) targeting the sequence 5=-CTTCAGACCCGCCAACAAA-3= of rat STAT3 were designed, and the corresponding lentivirus was produced by Shanghai GeneChem. A lentiviral vector targeting the scramble sequence 5=-TTCTCCGAACGTGTCACGT-3= was used as the negative control. Cardiomyocytes were infected with lentivirus-STAT3 siRNA at a multiplicity of infection (MOI) of ϳ50 to 200. After 3 days of infection, cells were serum starved for 24 h and then treated.
Real-time PCR. Total RNA was extracted by the TRIzol method and subjected to reverse transcription. The expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) was amplified by real-time PCR. The rat GAPDH expression was amplified as a reference standard. The following primers were used: ANP, sense 5=-ATAGATCTGCCCTCTTGAAAAGCAA-3= and antisense 5=-TCT-TCGGTACCGGAAGCTGTT-3=; BNP, sense 5=-CTGTCGC-CGCTGGGAGGTCAC-3= and antisense 5=-TGTCTTGAGACCTA-AGGACTC-3=; and GAPDH, sense 5=-ATCAAGAAGGTGGT-GAAGCA-3= and antisense 5=-AAGGTGGAAGAATGGGAGTTG-3=. Reactions were prepared in triplicate and heated to 95°C for 5 min, followed by 35 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s. The resulting relative increase in reporter fluorescent dye (SYBR green) emission was monitored with the use of the ABI PRISM7700 sequence detector (Applied Biosystems).
Immunofluorescence assay. For detection of STAT3 nuclear translocation, cardiomyocytes were cultured on glass coverslips and stimulated with or without NE for 60 min after pretreatment with propranolol. After treatment, cells were fixed with 4% paraform, permeabilized in 0.2% Triton X-100, and incubated with anti-STAT3 or anti-phospho-STAT3 antibody (1:100) at 4°C overnight and FITCconjugated AffiniPure goat anti-rabbit antibody (1:200; Santa Cruz Biotechnology) at 37°C for 1 h. Cells were counterstained with 5 g/ml Hoechst 33342 (Sigma-Aldrich) to visualize the nucleus.
For F-actin staining, cells were fixed with 4% paraform, permeabilized in 0.2% Triton X-100, and then incubated with TRITClabeled phalloidin (Sigma) for 30 min at room temperature.
STAT3 DNA binding activity. STAT3 DNA binding activity was detected by the use of STAT3 TransCruz oligonucleotide agarose conjugates (coupling of the specific sequence of STAT3: 5=-GATC-CTTCTGGGAATTCCTAGATC-3=; Santa Cruz Biotechnology).
Luciferase reporter assay. Cardiomyocytes were transfected with STAT3-driven promoter [2ϫ acute-phase response element (APRE)] firefly luciferase reporter plasmid and the internal control renilla luciferase reporter plasmid (phRL-TK; Promega) with the fugene 6 reagent (Roche) following the manufacturer's instructions. After transfection, cell extracts were assayed by the use of the DualLuciferase Reporter Assay System (Promega). To construct the STAT3-driven promoter, the 2ϫ APRE sequence 5=-TCGACATC-CTTCTGGGAATTCTG-ATCCTTCTGGGA-ATTCTGGGTAC-3= was cloned into the multiple cloning site of the pGL3-TATA plasmid, which encodes a firefly luciferase gene containing a basic upstream TATA element.
Animal model of hypertrophy. Male C57BL/6 mice (age 10 wk, obtained from the Medical Experimental Animal Center of Peking University Health Science Center) were randomly divided into vehicle, phenylephrine (PE), and PE plus WP1066 groups. An osmotic minipump (model 1002; ALZET DURECT) was subcutaneously embedded in the back of mice under anesthesia with fresh 1.25% tribromoethanol (150 mg/kg ip) and kept warm with a heating pad. All surgical procedures were performed after confirming an anaesthetized state of mice (e.g., no response to toe pinching). After the surgery, mice were resuscitated gradually. PE (75 mg·kg Ϫ1 ·day Ϫ1 ), dissolved in 0.1 mM ascorbic acid, or 0.1 mM ascorbic acid was infused constantly for 7 days through minipumps. In the PE plus WP1066 group, mice also received 100 l WP1066 (20 mg/kg ip injection) every other day from 1 day before minipumps were loaded.
Echocardiography and evaluation of hemodynamics. Mice were anaesthetized with 1.5% isoflurane allowing spontaneous breathing. Echocardiographic images were obtained by use of a Vevo 770 ultrasound machine (Visualsonics, Toronto, Canada). For measurement of hemodynamics, a 1.4-F micromanometer conductance catheter (SPR-835; Millar Instruments, Houston, TX) was introduced through the right common carotid artery into the ascending aorta and then advanced into the left ventricle.
Organ weight data. Following deep anesthesia with 1.5% isoflurane, the mice were killed by cervical dislocation and then weighed. Hearts were excised, rinsed in PBS, and weighed. The tibia length of the left posterior limb was measured to normalize the heart weight.
Histological analysis. Excised hearts were fixed with 4% paraform overnight. Fixed hearts were embedded in paraffin and sectioned at 6-m thickness. Samples were stained with hematoxylin and eosin. Photomicrographs were quantified with use of Leica Q550 IW software to measure the cross-sectional area of cardiomyocytes (expressed as the transverse diameter of myocytes cut at the level of the nucleus).
Statistical analysis. Data are expressed as means Ϯ SE. Differences between groups were determined by one-way ANOVA or unpaired t-tests using Prism 5 (GraphPad Software, La Jolla, CA). P Ͻ 0.05 was considered statistically significant.
RESULTS

␣ 1 -AR stimulation induced STAT3 activation.
Because phosphorylation of STAT3 on tyrosine residues is necessary for its activation, we first tested the effect of ␣ 1 -AR on STAT3 phosphorylation. As shown in Fig. 1A , activation of ␣ 1 -AR time dependently induced the phosphorylation of STAT3 on tyrosine 705, which peaked at 60 min. The ␣ 1 -AR-induced STAT3 phosphorylation was suppressed by pretreatment with prazosin, a selective ␣ 1 -AR antagonist (Fig. 1B) , further confirming the specific activation of ␣ 1 -AR on the phosphorylation of STAT3.
As a transcriptional factor, the role of STAT3 is mainly in the nucleus. Thus we determined by fluorescence microscopy whether ␣ 1 -AR stimulation might change the subcellular localization of STAT3. As shown in Fig. 1C , under the basal circumstance, STAT3 was mainly distributed in the cytoplasm. . E: cardiomyocytes were cotransfected with STAT3-driven promoter and renilla luciferase plasmid for 24 h. STAT3 transcriptional activity was converted to relative luciferase activity and tested by ␣1-AR antagonist prozasin. Values are means Ϯ SE. **P Ͻ 0.01 vs. control (con); ##P Ͻ 0.01 vs. norepinephrine (NE)/ propranolol (n ϭ 3).
After ␣ 1 -AR stimulation, STAT3 aggregated at the nucleus, which indicates nuclear translocation of STAT3.
To explore whether the STAT3 nuclear translocation was linked to functional activation, we monitored the subcelluar distribution of tyrosine phosphorylated STAT3. As shown in Fig. 1C (bottom) , tyrosine phosphorylated STAT3 expression was nearly invisible under the basal condition. After ␣ 1 -AR stimulation, it increased and aggregated mainly at the nucleus. Thus ␣ 1 -AR stimulation caused an activation-related translocation of STAT3 from the cytoplasm to the nucleus.
We investigated STAT3 binding to DNA to achieve transcriptional activity. We used oligonucleotide-conjugated agaroses, which contain the consensus binding sequence of STAT3, to enrich the DNA-bound STAT3. The result showed that ␣ 1 -AR stimulation potently increased sequence-specific DNA binding activity of STAT3 (Fig. 1D) .
We also examined STAT3 transcriptional activity, a direct evidence of STAT3 activation. As shown in Fig. 1E , ␣ 1 -AR activation enhanced STAT3-driven promoter (2ϫ APRE) luciferase activity. This enhancement was abolished by the ␣ 1 -AR antagonist prazosin, which further confirms the specific activation of ␣ 1 -AR on STAT3 transcriptional activity.
STAT3 mediated ␣ 1 -AR-induced hypertrophy in cardiomyocytes. We next examined the importance of STAT3 in ␣ 1 -AR-induced hypertrophic growth in cardiomyocytes. First, pretreatment with 10 mol/l WP1066, a STAT3 inhibitor, significantly inhibited the ␣ 1 -AR-induced STAT3 activation ( Fig. 2A) , as well as fetal gene ANP and BNP expression (Fig. 2, B and C) . Furthermore, 500 mol/l cell-permeable STAT3 inhibitor peptide (Calbiochem) significantly inhibited ␣ 1 -AR-induced protein synthesis as measured by [ 3 H]leucine incorporation assay (Fig. 2D) .
To further confirm the role of STAT3 in ␣ 1 -AR-induced cardiomyocyte hypertrophy, we used a lentivirus containing rat STAT3 siRNA. Efficient transfection was first observed, with Ͼ90% of cells transfected at an MOI of 150 (data not shown). The knockdown effect and specificity of lentivirus-STAT3 siRNA were further confirmed. STAT3 protein had almost no expression in STAT3 knockdown cells at MOI 50 and 200, compared with negative control cells (lentivirus-Scramble; Fig.  2E ). In addition, the expression of STAT1 was not decreased in STAT3 knockdown cells, which confirms the specificity of the lentivirus-STAT3 siRNA in neonatal rat cardiomyocytes.
[ 3 H]leucine incorporation assays revealed that knocking down STAT3 by lentivirus-STAT3 siRNA inhibited the ␣ 1 -AR-induced protein synthesis in cardiomyocytes, compared with lentivirus-Scramble (Fig. 2F) . Consistently, lentivirus-STAT3 siRNA could inhibit the increase in cell surface area by ␣ 1 -AR activation (Fig. 2G) . Thus the STAT3 pathway plays an important role in ␣ 1 -AR-induced cardiomyocyte hypertrophy.
STAT3 mediated PE-infusion-induced heart hypertrophy in mice.
To determine the role of STAT3 in ␣ 1 -AR-induced heart hypertrophy, we created a PE infusion animal model. The anatomic and functional data for mice subjected to different treatments are summarized in Table 1 . In our study, the hypertrophy was not a result of increased hemodynamic load induced by PE but rather an effect of PE on ␣ 1 -AR in the heart, because the blood pressure did not differ between PE and vehicle treatment (Table 1) .
To further clarify the role of STAT3 in ␣ 1 -AR-induced cardiac hypertrophy, we observed the effect of WP1066 on PE-induced cardiac hypertrophy. First, we confirmed the effect of WP1066 on STAT3 activity in the heart. As shown in Fig. 3A , administration of WP1066 (20 mg/kg ip injection) decreased the level of phosphorylated STAT3 relative to vehicle-treated controls.
Next, we investigated the effect of WP1066 on PE-induced cardiac hypertrophy. End-diastolic left ventricular posterior wall thickness, as assessed by echocardiography, was significantly increased in PE-treated mice compared with control mice, whereas WP1066 could greatly inhibit this effect ( Fig.  3B ; Table 1 ). Likewise, the ratios of heart weight to body weight and heart weight to tibia length were significantly decreased in mice receiving PE plus WP1066 compared with mice receiving PE alone ( Fig. 3C ; Table 1 ). Furthermore, histological analysis revealed that WP1066 markedly inhibited the PE-induced increase in cardiac myocyte cross-sectional area (Fig. 3D) . Thus PE induced significant cardiac hypertrophy through stimulation of ␣ 1 -AR, and inhibition of STAT3 could inhibit PE-induced cardiac hypertrophy.
Transactivated EGFR mediated ␣ 1 -AR-induced STAT3 activation. Because EGFR is an important receptor tyrosine kinase activating STAT3, we examined whether EGFR might be involved in ␣ 1 -AR-induced STAT3 activation in cardiomyocytes. We first studied the effect of ␣ 1 -AR on the phosphorylation of EGFR. Treating of cardiomyocytes with NE induced Values are means Ϯ SE; n, number of mice. LVPWd, left ventricular posterior wall diameter in diastole; LVIDd, left ventricular end-diastolic inner dimension; LVIDs, left ventricular end-systolic inner dimension; LVEDP, left ventricular end-diastolic pressure; dp/dtmax and dp/dtmin, maximal positive and negative derivative of intraventricular pressure. *P Ͻ 0.05 and ‡P Ͻ 0.01 vs. vehicle. †P Ͻ 0.05 and §P Ͻ 0.01 vs. PE. tyrosine phosphorylation of EGFR (within 5 min; Fig. 4A ). The phosphorylation of EGFR was suppressed by pretreatment with the ␣ 1 -AR antagonist prazosin (Fig. 4B) , which confirms the specific activation of ␣ 1 -AR on the phosphorylation of EGFR. As a Gq-coupled receptor, ␣ 1 -AR is generally considered to trigger response through Gq protein-mediated signaling. Our research showed that both GP antagonist-2A (10 mol/l), a peptide that selectively inhibits activation of Gq proteins (Merck KgaA), and RO-318220 (1 mol/l), a potent and specific PKC inhibitor (Calbiochem), inhibited ␣ 1 -AR-induced EGFR phosphorylation (Fig. 4, C and D) . These results suggest that ␣ 1 -AR could transactivate EGFR through Gq/PKC pathway in neonatal rat cardiomyocytes.
Next, to further determine whether the EGFR signal pathway has an important role in ␣ 1 -AR-induced hypertrophy, we examined the effect of a selective EGFR tyrosine phosphorylation inhibitor AG1478 on myocardial hypertrophy. Pretreatment with 3 mol/l AG1478 significantly inhibited the ␣ 1 -ARactivated increase in cell surface area (Fig. 4E) , as well as fetal gene ANP and BNP expression (Fig. 4, F and G) .
To investigate the involvement of EGFR in ␣ 1 -AR-induced STAT3 activation, we examined the effect of AG1478 on STAT3 activation. As shown in Fig. 4 , H and I, ␣ 1 -AR-induced STAT3 tyrosine phosphorylation and its transcriptional activity were significantly inhibited by 3 mol/l AG1478.
Thus EGFR transactivation plays an important role in ␣ 1 -AR-induced STAT3 activation and cardiac hypertrophy.
Matrix metalloproteinase and a disintegrin and metalloproteinase, heparin-bound-EGF mediated ␣ 1 -AR-induced STAT3
activation. Binding with corresponding ligands, which are released from their membrane-tethered precursors, represents key elements in transactivation of EGFR. Therefore, we further investigated whether STAT3 activation was sensitive to the inhibition of a soluble EGFR ligand, heparin-bound EGF (HB-EGF). We examined the effects of heparin and HB-EGF neutralizing antibody (R&D Systems) on ␣ 1 -AR-induced EGFR transactivation and STAT3 activation. Heparin can associate with cleaved HB-EGF to prevent the release of the mature growth factor into the conditioned medium, and HB-EGF neutralizing antibody acts as a competitive ligand to prevent HB-EGF binding with EGFR. The results show that both heparin (100 g/ml) and HB-EGF neutralizing antibody (20 g/ml) attenuated ␣ 1 -AR-induced EGFR phosphorylation (Fig. 5A) as well as STAT3 tyrosine phosphorylation and its transcriptional activity (Fig. 5, B and C) .
Several studies have revealed the crucial role of metalloproteinases [matrix metalloproteinase (MMP) and a disintegrin and metalloproteinase (ADAM)] in the enzymatic conversion of pro-HB-EGF to HB-EGF. To determine whether the activity of metalloproteinases is involved in ␣ 1 -AR-induced STAT3 activation, we used two metalloproteinase inhibitors, MMP inhibitor III (10 mol/l), a broad-spectrum MMP/ADAM in- hibitor (Calbiochem), and Bips (10 mol/l), a MMP-2/-9 inhibitor II, and measured STAT3 activation. First, as shown in Fig. 5D , ␣ 1 -AR-induced EGFR tyrosine phosphorylation was indeed significantly inhibited by MMP inhibitor III and Bips. As expected, the two metalloproteinase inhibitors also significantly blocked STAT3 tyrosine phosphorylation and its transcriptional activity subsequently (Fig. 5, E and F) .
Thus the MMPs/ADAM-dependent, HB-EGF shedding-mediated EGFR transactivation pathway modulates ␣ 1 -AR-induced STAT3 activation.
DISCUSSION
The functions of ␣ 1 -AR in the cardiovascular system have been extensively studied (5) . Under physiological conditions, ␣ 1 -AR is considered involved in neurohumoral responses such as cardiac inotropy (24) and peripheral vasoconstriction (19, 30) . Under pathological conditions, ␣ 1 -AR becomes chronically activated and contributes to the development of myocardial hypertrophy (22, 39) , proliferation of fibroblasts (31), and neointimal hyperplasia of vascular smooth muscle cells (5, 46) . The signaling mechanism of ␣ 1 -AR is described as follows. ␣ 1 -AR activates phospholipase C␤ via G␣q proteins. This causes generation of diacylglycerol and inositol trisphosphate, which in turn causes activation of protein kinase C and release of calcium, respectively. The ␣ 1 -AR-induced hypertrophic response usually involves activation of members of the MAPK family, as well as the phosphatidylinositol 3-kinase/Akt pathway. In recent years, many signaling molecules other than classical ones were proposed. For example, production of mitochondrial reactive oxygen species is a new event in the pathway in which ␣ 1 -AR modulates vascular wall growth and cardiac hypertrophy (10) . Despite much research into ␣ 1 -AR-induced hypertrophy, the overall framework has not been completed.
In this study, our findings demonstrated STAT3 as a novel ␣ 1 -AR downstream target to mediate hypertrophy. Recent studies suggested that the activation of STAT3 has two different modes, phosphorylation dependent (40) and independent (42), which both play an important role in the development of cardiac hypertrophy. In short-term stimulation of the receptor causing the initial stage of cardiac hypertrophy, STAT3 activation normally requires Tyr705 phosphorylation (9) that enables dimerization, accumulation in the nucleus, and binding to GAS sequences to induce hypertrophy-related genes such as c-fos, c-myc, and Bcl-xL (3, 9) . In the chronic phase of hypertrophy, unphosphorylated STAT3 (U-STAT3) may also enter the nucleus through physical interaction with other transcription factors or cofactors (20) . Potential target genes of U-STAT3 include TGF-␤, OPN, CTGF, and RGS2 (43) , which may influence remodeling associated with heart failure. A recent study (43) revealed that chronic activation (several months) of ANG II type 1 receptor induces an increase in STAT3 mRNA and protein but not phosphorylated STAT3 on Y705 residues. Hence, P-STAT3 and U-STAT3 have roles in cardiac hypertrophy through different mechanisms depending on sequence context. In our study, we observed that short-term stimulation of ␣ 1 -AR-induced STAT3 activation is phosphorylation dependent, which is further manifested in the increased Tyr705 phosphorylation, nuclear translocation linked with tyrosine phosphorylation, DNA binding activity of STAT3, and as an important transcription factor, finally increased transcriptional activity of STAT3 in neonatal rat cardiomyocytes.
We next explored the pathophysiological significance of STAT3 activation and found STAT3 plays an important role in ␣ 1 -AR-induced hypertrophy. By using a STAT3 inhibitor WP1066 and a STAT3 inhibitor peptide, we found a decreased ␣ 1 -AR-induced increase in protein synthesis and cell size. Compared with these pharmacological approaches, which only suppress the activity of STAT3, siRNA-mediated STAT3 gene silencing is more specific and potent. Thus we transfected cardiomyocytes with lentivirus-STAT3 siRNA and confirmed that it could also significantly inhibit the increase in protein synthesis as well as cell surface area induced by ␣ 1 -AR. In the process of STAT3 gene silencing, we noted the increased expression of STAT1. However, our experiments showed that stimulation of ␣ 1 -AR could not activate STAT1 (data not shown), suggesting that STAT1 was no involved in the ␣ 1 -AR-induced hypertrophy pathway in our study. In addition, we provide evidence of enhanced STAT3 activation in the PEinfused heart of adult mice, which showed exacerbated cardiac hypertrophy compared with control mice. As expected, the STAT3 inhibitor WP1066 decreased STAT3 tyrosine phosphorylation. Consistent with our in vitro results, administration of WP1066 markedly ameliorated cardiac hypertrophy. The ratios of heart weight to body weight and heart weight to tibia length were lower in mice receiving WP1066. The crosssurface area of cardiomyocytes was also significantly decreased in WP1066-treated mice.
As an important transcription factor, STAT3 is involved in some forms of cardiac hypertrophy. Cardiac-specific overexpression of STAT3 in transgenic mice leads to myocardial hypertrophy (19) . As well, impaired downregulation of STAT3 activation under certain pathological conditions such as myocardial infarction aggravates the cardiac inflammatory response, adverse ventricular remodeling, and heart failure (14, 18) . Recent evidence in adult rat ventricular myocytes indicates that STAT3 has an important role in interleukin-6-induced c-fos gene expression, BNP secretion, protein synthe- sis, and hypertrophy (34) . Besides the cytokine signaling pathway, pressure-overload and renin angiotensin system-related cardiac hypertrophy also require STAT3. In terms of the effect of STAT3 in sympathetic activation-induced cardiac hypertrophy, our previous studies showed that the ␤-AR agonist isoproterenol potently induced activation of STAT3 and the reexpression of atrial natriuretic factor in neonatal rat cardiomyocytes (44) , which agrees with the results of this study.
We found that ␣ 1 -AR-induced phosphorylated STAT3 activation is linked to cardiac hypertrophy. However, ␣ 1 -AR itself does not have intrinsic tyrosine kinase activity, and it should not be able to induce tyrosine phosphorylation of multiple signal proteins directly, which suggests an involvement of tyrosine kinases in GPCR-triggered signals (2) . Recent studies have suggested that some receptor tyrosine kinases such as receptors for EGF (16) , VEGF (36) , and PDGF (12) may be used by GPCRs through the process transactivation as intermediate molecules to mediate the effect of GPCRs. In the present study, we found that ␣ 1 -AR could transactivate EGFR, so EGFR transactivation may mediate ␣ 1 -AR-induced STAT3 activation. Use of the selective EGFR tyrosine phosphorylation inhibitor AG1478 significantly inhibited ␣ 1 -AR-induced STAT3 tyrosine phosphorylation and its transcriptional activity. As we know, EGFR is activated by endogenous ligands such as EGF and HB-EGF. HB-EGF is a heparin-binding member of the EGF family and able to bind EGF receptors with higher affinity than EGF itself. Our further research showed that the addition of neutralizing anti-HB-EGF antibody, as well as pretreatment with heparin, abolished the activation of STAT3 induced by ␣ 1 -AR. Like other members of the EGF family, HB-EGF is synthesized as a transmembrane precursor (pro-HB-EGF) and then proteolytically processed into the mature form. This proteolytic processing was reported to be regulated by a kind of peptidase, metalloproteinases, whose catalytic activity is dependent on the coordinated Zn 2ϩ (32) . Metalloproteinases are divided into two groups: MMPs and ADAMs, which are important for the degradation of extracellular matrix and the proteolysis of many growth factors, cytokines, and cell adhesion molecules (4) . Previous studies (30, 31) have shown that metalloproteases are responsible for the shedding of pro-HB-EGF and the subsequent transactivation of EGFR, since these events can be efficiently inhibited by various metalloprotease inhibitors. However, the contribution of each MMP/ADAM appears to be highly dependent on specific stimulus and cellular background. For example, MMP-7 has been reported to mediate EGFR transactivation in rat mesenteric arteries (11) , while ADAM17 is implicated in ANG II-induced EGFR transactivation in COS7 cells (26) . In our study, we found that both MMP inhibitor III, a broad-spectrum MMP/ADAM inhibitor, and Bips, a MMP-2/-9 inhibitor, inhibited ␣ 1 -AR-induced EGFR transactivation and STAT3 activation. Therefore, the MMP/ADAMdependent shedding of HB-EGF to transactivate EGFR is an essential event for ␣ 1 -AR-induced STAT3 activation in neonatal rat cardiomyocytes.
Up to now, there is no exact mechanism regarding the ␣ 1 -AR-EGFR transactivation pathway in cardiac hypertrophy. According to previous studies of other GPCRs, the generally believed mechanism is that transactivated EGFR could activate its well-known downstream kinase e.g., ERK, which subsequently phosphorylates some of the protein substrates (other protein kinase, structural proteins, etc.) to promote hypertrophy (25, 28, 35) . Recently, some novel molecules other than classical ones were also proposed. For example, the work of Guo et al. (10) implicates p66Shc, which is an adapter protein that has normally emerged as a pivotal regulator of oxidative stress signals in ␣ 1 -AR-induced hypertrophic pathway. Their research found that ␣ 1 -AR increased p66Shc phosphorylation via transactivation of EGFR. In addition to regulating oxidative stress responses through the ROS-AKT-FOXO3A phosphorylation pathway, the downregulation of p66Shc markedly induced cardiac hypertrophy. This article provided a new viewpoint about the EGFR transactivation pathway. Besides those reported protein kinase and adapter proteins, our study found that an important transcription factor STAT3 also serves as a downstream effector of EGFR in ␣ 1 -AR-induced hypertrophy, which further extends the study of EGFR transactivation pathway.
In this report, we describe a novel mechanism by which the activation of STAT3, mainly through transactivation of EGFR, plays an essential role in ␣ 1 -AR-induced cardiac hypertrophy (Fig. 6 ). Such a mechanism may help better understand the signal transduction of ␣ 1 -AR-mediated cardiac hypertrophy and the cross-talk between GPCR and receptor tyrosine kinase signaling pathways, which provides a new theoretical basis for the treatment of cardiac hypertrophy.
